Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels

[1]  J. Rojas-Rivera,et al.  Novel Treatments Paradigms: Membranous Nephropathy , 2023, Kidney international reports.

[2]  Gaosi Xu,et al.  Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis , 2022, International Urology and Nephrology.

[3]  Gaosi Xu,et al.  Efficacy and safety of 12 immunosuppressive agents for idiopathic membranous nephropathy in adults: A pairwise and network meta-analysis , 2022, Frontiers in Pharmacology.

[4]  L. Reinhard,et al.  Membranous nephropathy: new pathogenic mechanisms and their clinical implications , 2022, Nature Reviews Nephrology.

[5]  Gaosi Xu,et al.  Treatment of Idiopathic Membranous Nephropathy for Moderate or Severe Proteinuria: A Systematic Review and Network Meta-Analysis , 2022, International journal of clinical practice.

[6]  S. Palmer,et al.  Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis , 2022, Journal of Nephrology.

[7]  Yuan Chen,et al.  Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies. , 2022, Nephrologie & therapeutique.

[8]  A. Ortíz,et al.  Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy , 2021, Drugs.

[9]  Gabrielle J Williams,et al.  Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome. , 2021, The Cochrane database of systematic reviews.

[10]  E. Frangou,et al.  The management of membranous nephropathy - an update. , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  Ashwani Kumar,et al.  Immunosuppressive Therapy in Primary Membranous Nephropathy with Compromised Renal Function , 2021, Nephron.

[12]  B. Rovin,et al.  KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. , 2021, Kidney international.

[13]  J. Wetzels,et al.  Anti-PLA2R1 Antibodies as Prognostic Biomarker in Membranous Nephropathy , 2021, Kidney international reports.

[14]  A. Bomback,et al.  Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO. , 2021, Kidney360.

[15]  L. Gesualdo,et al.  Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. , 2021, Journal of the American Society of Nephrology : JASN.

[16]  Shi-yuan Wang,et al.  Efficacy and cost of different treatment in patients with idiopathic membranous nephropathy: A network meta-analysis and cost-effectiveness analysis. , 2021, International immunopharmacology.

[17]  J. Wetzels,et al.  The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. , 2020, Kidney international.

[18]  S. Baldovino,et al.  Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli’s regimen in membranous nephropathy , 2020, Journal of Nephrology.

[19]  Qiyan Zheng,et al.  Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic review and network meta-analysis , 2019, BMJ Open.

[20]  P. Lin,et al.  Efficacy and safety of rituximab therapy for membranous nephropathy: a meta-analysis. , 2018, European review for medical and pharmacological sciences.

[21]  A. Bomback,et al.  Membranous Nephropathy: Approaches to Treatment , 2018, American Journal of Nephrology.

[22]  J. Wetzels,et al.  Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. , 2018, Kidney international.

[23]  G. Remuzzi,et al.  Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[24]  G. Remuzzi,et al.  Treatment of membranous nephropathy: time for a paradigm shift , 2017, Nature Reviews Nephrology.

[25]  A. S. Medrano,et al.  Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens , 2015, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[26]  J. Klein,et al.  Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. , 2014, The New England journal of medicine.

[27]  U. Panzer,et al.  M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[28]  Elie A Akl,et al.  GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. , 2013, Journal of clinical epidemiology.

[29]  Gordon H Guyatt,et al.  GRADE guidelines: 2. Framing the question and deciding on important outcomes. , 2011, Journal of clinical epidemiology.

[30]  L. Kiemeney,et al.  Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. , 2011, The New England journal of medicine.

[31]  David M. Beck,et al.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. , 2009, The New England journal of medicine.

[32]  A. Lupo,et al.  A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. , 1998, Journal of the American Society of Nephrology : JASN.

[33]  OUP accepted manuscript , 2021, Nephrology Dialysis Transplantation.

[34]  E. S. St Clair,et al.  Good and bad memories following rituximab therapy. , 2010, Arthritis and rheumatism.